Moxifloxacin

Adult treatment of community-acquired pneumonia, uncomplicated/complicated skin and skin-structure infection, complicated intra-abdominal infection, plague treatment/prophylaxis, acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis, caused by the label’s designated susceptible organisms. Reserve sinusitis and chronic-bronchitis exacerbation treatment for patients without alternative options because serious risks may outweigh benefit. Plague efficacy approval rests on animal studies because human efficacy trials were infeasible. Use culture/local susceptibility information; do not infer UTI, MRSA, viral or empiric every-pathogen coverage.

Vigamox treats bacterial conjunctivitis caused by specified susceptible organisms; not a general indication for viral eye irritation or systemic infection. Other 0.5% eye formulations may have different excipients, age limits and dosing; see the historical comparison in dosage.

Oral tablet with or without food; maintain appropriate hydration. Take ≥4 hours before or ≥8 hours after magnesium/aluminum antacids, iron/zinc products, sucralfate or buffered didanosine. Missed tablet: take only if ≥8 hours remain before the next dose; otherwise skip; never double. IV selected 400 mg/250 mL premix: infuse over 60 minutes; no bolus or other injection route. Do not add drugs or infuse simultaneously through the same line; sequential shared-line use requires compatible flushing. IV-to-oral conversion uses the same dose when the clinician judges appropriate. Listed label durations are not universal guideline or self-treatment rules.

Current Vigamox: 1 drop in affected eye three times daily for 7 days; safety/effectiveness established at all ages. Historical Moxeza August 2021 PI: 1 drop in affected eye(s) twice daily for 7 days, with use below 4 months unestablished. Historical formulation is not for intracameral injection; it can damage corneal endothelium. No active Moxeza record was returned by the current API query; obtain exact current package/status review before use rather than substitute its historical regimen for Vigamox.

Systemic moxifloxacin: history of hypersensitivity to moxifloxacin or another quinolone. Current Vigamox: moxifloxacin, other quinolone or ingredient hypersensitivity. Systemic myasthenia, QT-risk and prior serious-reaction restrictions are important avoidance warnings, not an invented formal section 4 list.

Oral/IV labels warn of disabling potentially irreversible tendon, peripheral nerve and CNS reactions; stop and avoid further fluoroquinolone use after serious reactions. They also warn of myasthenia-gravis exacerbation and reserve use for specified sinusitis/bronchitis indications without alternatives. Selected Vigamox has no boxed warning; do not transfer the systemic box to its label.

Systemic common reactions include nausea, diarrhea, headache and dizziness; serious events are described above. Vigamox may cause ocular pain/discomfort, dryness, redness, itching, tearing or vision changes. Systemic excess dosing needs professional assessment, hydration/support and ECG monitoring for QT risk; dialysis removes only a small fraction. No home gastric-emptying/charcoal protocol or reassurance based on reported tolerated overdoses. Selected eye label supplies no overdose algorithm.

Separate oral dosing ≥4 hours before or ≥8 hours after magnesium/aluminum antacids, sucralfate, iron/zinc supplements/multivitamins and buffered didanosine. This interval is not an eye-drop instruction. Food/yogurt is not automatically prohibited by the label.

Closely monitor INR/anticoagulation with warfarin. Monitor glucose with antidiabetic therapy. Avoid class IA / III antiarrhythmics and other QT-prolonging drugs; assess electrolytes. NSAIDs may increase CNS stimulation/seizure risk; systemic corticosteroids increase tendon-risk concerns. No independent anticoagulant or glucose-medication dose change algorithm.

Vigamox interaction studies were not conducted. In-vitro CYP results suggest little effect on metabolism through studied CYP enzymes; do not infer that all drug combinations have proven safety.

Systemic labeling requires no adjustment for renal impairment, including HD/CAPD, or Child–Pugh A, B or C hepatic impairment. However, hepatic metabolic disturbance can increase QT risk: use caution and monitor ECG in cirrhosis. Dialysis removal is small and does not establish an overdose remedy. Ophthalmic labeling supplies no numeric renal/hepatic table; do not copy systemic exposure assumptions to drops.

Systemic efficacy below 18 is unestablished; pediatric complicated-intra-abdominal trial did not demonstrate safety/efficacy and juvenile animals develop arthropathy. No pediatric systemic regimen provided. Vigamox effectiveness/safety are established at all ages, including neonates. Older systemic users have greater tendon, aortic and QT-risk concerns, especially with corticosteroids; assess actual risk rather than invent an age-only reduced dose.

Systemic human pregnancy risk data are lacking; animal findings support potential fetal harm and require counseling/benefit-risk review. Human milk presence is unknown; consider breastfeeding benefit, maternal need and infant risk. Ophthalmic pregnancy studies are inadequate; systemic exposure after eye drops is much lower, but human milk/infant data remain limited. No universal pregnancy-safe claim or automatic milk-discard interval.

Bactericidal inhibition of DNA gyrase/topoisomerase II and topoisomerase IV interferes with bacterial DNA replication, transcription, repair and division. Target mutations, permeability changes or efflux can cause resistance; cross-resistance with other fluoroquinolones occurs. Use organism/site-specific susceptibility rather than a universal coverage list.

Oral bioavailability about 90%; systemic half-life about 12 hours, protein binding 30–50%. Metabolism uses glucuronide/sulfate conjugation rather than CYP450; parent/metabolites are eliminated in urine/feces. Lack of CYP metabolism does not eliminate pharmacodynamic interactions. Vigamox bilateral dosing produced systemic concentrations far below 400 mg systemic dosing; the ophthalmic study estimated plasma half-life 13 hours, not a reason to reduce prescribed drop frequency.

Before systemic therapy assess quinolone reactions, tendon/neurologic history, myasthenia, QT drugs/electrolytes, aortic risk, organ disease, glucose medicines and anticoagulation. Monitor clinical response, INR/glucose in relevant combinations and ECG for cirrhosis/risk contexts. For drops, assess bacterial diagnosis, vision, allergy and treatment response. No universal lab timetable or therapeutic drug level invented.

Take the exact prescribed course unless serious toxicity requires immediate stopping and replacement review. Rest and avoid exercise with tendon symptoms. Seek urgent care for serious allergy, severe hypoglycemia, syncope, sudden chest/back/abdominal pain or severe neurologic symptoms; report delayed severe diarrhea. Limit sun/UV exposure, follow cation timing and missed-dose rules. Drops: do not touch tip to surfaces, avoid contact lenses during conjunctivitis and never inject. No sharing or leftover-antibiotic self-treatment.

Strength / imprint

400 mg moxifloxacin equivalent; modified capsule-shaped dull-red film-coated tablet, E-18 on one side.

Selected package

AvPAK institutional unit dose; NDC 50268-576-13, 10 tablets/card and 3 cards/carton.

Status

Prescription oral ANDA product; other manufacturers’ appearance requires their label.

IV premix

400 mg/250 mL (1.6 mg/mL) in 0.8% sodium chloride; single-dose bag, NDC 67457-323-25.

Vigamox

0.5% base =5 mg/mL; hydrochloride 5.45 mg/mL. Harrow 3 mL fill in 4 mL bottle, NDC 82667-700-03.

Historical comparison

Moxeza is also 0.5% but contains different excipients and has a different historical regimen. No current-active-label or stock claim.

Routes

Oral, prescribed IV infusion, or topical ophthalmic; no substitution by volume or intraocular injection.

Oral tablets 20–25°C; avoid high humidity. IV premix 25°C with 15–30°C excursions; do not refrigerate because it precipitates; inspect solution/container, no additives or series connections, discard unused single-dose portion. Vigamox 2–25°C; keep tip uncontaminated and follow package expiration. No common opening-discard interval or historical Moxeza storage rule applied to current drops.